1. Market Research
  2. > Biotechnology Market Trends
  3. > Biopharmaceutical

Biopharmaceutical Sector: Get Market Research and Figures

  • Currently 4/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
10 votes

Global Biopharmaceutical Industry

The global biopharmaceutical industry (a part of the biotechnology market) is currently worth over $145 billion, according to research conducted by BioPlan Associates. The industry should exceed $167 billion in 2015, says IMARC. 

Biopharmaceuticals are used in the prevention and treatment of disease, and there are over 300 approved biopharmaceuticals on the market, with many in clinical development yet to come. The market has benefited from the need for pharmaceutical manufacturers to boost output, but it has a high risk factor, with only three out of 10 drugs that pass to the clinical phase receiving market clearance.

Cost containment and biosimilar entry in developed markets continue to see slow growth, but the market should expand thanks to biopharmaceutical capacity to outperform traditional small molecule drugs. Over the coming five-year period, factors such as development of emerging markets and a rich late-stage pipeline are expected to fuel growth.

Key Market Segments

The world biosimilar market is expected to record yearly growth in excess of 50% between 2010 and 2015, reports RNCOS. Market growth is being driven by factors such as costly drugs, high pharmaceutical expenditure and a global aging population. Market expansion will be further fuelled by expiring patents and the increasing cost of drugs. Sandoz is the leading company operating in the global biosimilars market, recording the highest sales. Teva and Hospira are developing a biosimilar product range.

The global enzyme market is expected to exceed $7.5 billion in 2015, reports Freedonia, and it should surpass yearly growth of 5%. The fastest rate of growth will be recorded in smaller markets such as the Africa/Middle East region, and Central and South America. Asia-Pacific is expected to record strong growth, while the EU and North America are forecast to record below-average growth.

The global protein therapeutics market is forecast to see yearly growth of 13% between 2012 and 2014, reports RNCOS. Increased investment and the introduction of new protein therapeutics will fuel market  expansion. Protein therapeutics have been recording a high rate of growth in recent years, vital to the treatment of many diseases. Protein therapeutics are particularly efficient due to their targeted approach, which allows the treatment of disease with little or no negative impact on healthy organs. Protein therapies are necessary in a healthcare landscape, witnessing rapidly rising rates of chronic illnesses like cardiovascular diseases, diabetes and cancer.

The cancer monoclonal antibodies market is expected to grow at a yearly rate in excess of 5% between 2012 and 2015, according to RNCOS. Cancer monoclonal antibodies are used to treat tumors with a high degree of specification. The market is driven by increasing prevalence of cancer and the need for more innovation research. The industry is witnessing rising consolidation.

Read more »


You might be interested in these related markets:

24/7 Customer Support

Talk to Sam

+1 718 473 0872

1-10 of about 5 700 reports

Global Biopharmaceutical Industry

  • January 2015
    6 pages
  • Nigeria  


View report >

Biopharmaceutical Analysis in the US

  • May 2016
    23 pages
  • Biopharmaceutic  

  • United States  

View report >

Biopharmaceutical Supply in Bosnia and Herzegovina and Europe Forecast

  • January 2016
    5 pages
  • Biopharmaceutic  

    Drug and Medica  

  • Bosnia and Herz  


View report >

Biopharmaceutical Supply in Japan

  • January 2016
    6 pages
  • Biopharmaceutic  

  • Japan  

View report >

Biopharmaceutical Industry in France

  • January 2014
    14 pages
  • Biopharmaceutic  

  • France  

View report >

Biopharmaceutical Industry in Germany and the US

  • July 2015
    14 pages
  • Biopharmaceutic  

  • Germany  

    United States  

View report >

Biopharmaceutical Industry in Italy

  • January 2015
    11 pages
  • Biopharmaceutic  

  • Italy  

View report >

Biopharmaceutical Industry in the UK

  • January 2016
    8 pages
  • Monoclonal Anti  



  • United Kingdom  

View report >

Biopharmaceutical Markets in Canada Forecast

  • November 2015
    16 pages
  • Biopharmaceutic  

  • Canada  

View report >

Biopharmaceutical Industry in Brazil

  • July 2015
    13 pages
  • Biopharmaceutic  


  • Brazil  

    United States  

View report >

Search in Biopharmaceutical Industry (About 5 700 reports)
Parent industry: Biotechnology
Related industries: Biological Therapy, Biomaterial, Genetically Modified Organism, Genomics

About 2 900 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 99 - $ 9 188)

Rheumatoid Arthritis: KOL Insight

Rheumatoid Arthritis: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Leading brands under threat as biosimilars and new pipeline drugs hit the market Key opinion leaders (KOLs) say Rheumatoid Arthritis (RA) treatment is in for a shakeup thanks to anti-TNF biosimilars, new ...

Biosimilars And Follow-on Biologics’ Trends, R&d And ...

February 2016 $ 7 019

Frontier Pharma: Gastric Cancer - Early Stage Pipeline ...

March 2016 $ 6 995

Global Markets And Manufacturing Technologies For Prote ...

May 2016 $ 6 650

Epiomic Epidemiology Series: Growth Hormone Deficiency ...

May 2016 $ 6 172

Opportunity In The Indian Biopharmaceuticals Market - 2 ...

April 2016 $ 6 000

Opportunity In The Indian Protein A Media Market - 2016 ...

April 2016 $ 5 000

Global Viral Infections Market To 2021 - Promising New ...

April 2016 $ 4 995

Global Non-hematological Cancers Market To 2021 - Stron ...

April 2016 $ 4 995

Asthma Therapeutics In Asia-pacific Markets To 2021 - H ...

March 2016 $ 4 995

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.